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Degeneration of the intervertebral disc (IVD) is a contributory factor to the back pain experienced by some patients QUOTE "1" 1 and although conservative treatment will alleviate the symptoms for many, for some spinal fusion becomes their only option. Spinal fusion has been shown to be effective in approximately two-thirds of patients treated QUOTE "2" 2, QUOTE "3" 3 and has been referred to as the ‘Gold Standard’ for treating back pain QUOTE "4,5" 4,5 QUOTE "" . It involves the degenerate IVD being fused to its adjacent vertebrae, thus immobilising the intervertebral space, reducing movement and alleviating the patient’s pain. The technique is both invasive and expensive and usually requires removal of disc material and replacement with autologous, allogeneic, xenogeneic or synthetic bone and/or metal ‘cages’ to replace the IVD QUOTE "6" 6, sometimes in combination with bone morphogenic proteins (BMPs) to stimulate new bone growth. Unfortunately, the procedure can still fail with non-fusion rates of up to 30% reported QUOTE "7" 7.
Normally, the human IVD does not mineralise, but under certain conditions, calcification of the disc can occur, particularly in the thoracic spine of males, with increasing age and where there is loss of disc height QUOTE "8" 8. Calcification in the disc has long been associated with several pathological conditions such as myositis ossificans progressive, juvenile rheumatoid arthritis and ankylosing spondylitis QUOTE "9" 9 where spinal fusion occurs first via bony spurs between vertebrae, followed by calcification of the IVD. Calcification, which is reported to occur more commonly in the outer annulus fibrosus than the central nucleus QUOTE "10" 10  has also been reported to occur following trauma, for example, 30% of children with calcification in their cervical discs had experienced previous severe trauma QUOTE "11" 11. In scoliotic patients, calcification has been identified in discs adjacent to calcified cartilage end-plates QUOTE "12" 12 particularly in regions subjected to altered loading; calcium deposits have also been found in degenerate disc tissue QUOTE "13" 13. 
In previous work from both our laboratory and others, the presence of local mesenchymal progenitor cells in IVD tissues has been highlighted within both the central nucleus pulposus (NP) and the outer annulus fibrosus (AF) of degenerate and non-degenerate human discs QUOTE "14" 14, QUOTE "15" 15, QUOTE "16" 16, QUOTE "17" 17, QUOTE "18" 18. They have shown that these cells can be driven down an osteogenic lineage by culturing in appropriate media; Nosikova et al QUOTE "19" 19 have also shown that bovine cells isolated from the AF are capable of mineralization and Hautschmann et al QUOTE "20" 20 induced ossification in lapine discs with BMP-2 and TGFβ.




Following ethical approval from Shropshire Research Ethics Committee (04/02/RJH) and Isle of Wight, Portsmouth and South East Hampshire Research Ethics Committee (09/H0501/95) and written informed consent, degenerate human IVD samples were obtained from 25 patients (14 males, 11 females, aged 41.0 ± 10.1 years) undergoing routine surgery for back and leg pain (16 with herniations and 9 with degenerative disc disease (DDD) (Table 1)). Bone marrow from iliac crest and tibial bone chips was obtained from 10 patients (3 males, 7 females, aged 48.5 ± 13.9 years) undergoing knee arthroplasty to provide mesenchymal stromal cells (MSCs) for positive controls of cells with the capacity to go down an osteogenic lineage.

Cell isolation and maintenance
Nucleus pulposus was identified macroscopically and dissected from IVDs obtained from 14 patients (aged 37 ± 10 years), minced and digested for 16 hours at 37ºC in 250 IU/mg collagenase (Type 2, Worthington Biochemical Corporation, Lakewood, USA) QUOTE "21" 21. Cells were filtered, washed and seeded at 5000 cells/cm2 and maintained in monolayer with ‘standard’ culture medium (DMEM/F12 (Life Technologies, Paisley, UK) containing 10% (v/v) foetal bovine serum (FBS; Life Technologies), 0.5% (v/v) ascorbic acid (10mg/ml solution in PBS; Sigma-Aldrich, St Louis, USA), 0.5% (v/v) gentamicin (Life Technologies), 1% (v/v) penicillin and streptomycin (Life Technologies) and 0.05% (v/v) fungizone (Life Technologies)) at 5% CO2 in a humidified atmosphere.  MSCs were also cultured in monolayer as previously described QUOTE "14" 14. All cells were passaged as standard by trypsinisation upon reaching 80% confluence.

Osteogenic differentiation in MONOLAYER (2D culture) 
Monolayer cultures of NP cells (at passage 1-4) and 100% confluency were treated with factors to induce osteogenic differentiation. For each experiment, cells from 3 different patients were utilised, and cells were seeded in triplicate in either 24- or 96-well plates for each patient and condition. All factors were compared to standard osteogenic medium which contained 100 nM dexamethasone (Sigma Aldrich), 50μM L-ascorbic acid-2-phosphate (Sigma Aldrich) and 10mM β-glycerophosphate (Sigma Aldrich) QUOTE "22" 22. Medium was replaced every 2-3 days for up to 21 days. We established both the effect of the individual components (and different combinations) of the osteogenic medium and also the following purported osteogenic inducers at concentrations previously found to promote osteogenesis in in vitro studies: (i) VitD3 (Sigma Aldrich) at 0.1, 1 or 10 nM  QUOTE "23,24,25" 23,24,25 QUOTE ""  QUOTE "" ; (ii) the 1-34 fragment of human PTH (Sigma Aldrich) at 1, 10 or 100 nM, either continuously or intermittently for 1 hour every 48 hours QUOTE "26,27,28" 26,27,28 QUOTE ""  QUOTE "" , and (iii) BMPs 2, 7 and 2/7 heterodimer (R&D systems, Minneapolis, USA) at 10 or 100ng/ml QUOTE "29,30" 29,30 QUOTE "" .  

Osteogenic differentiation in situ (3D culture) 
Disc tissue, with the macroscopic appearance of NP, from 11 patients aged 44 ± 12 years were dissected into similar sized pieces (approximately 5mm x 5mm) and maintained in explant culture whereby swelling of the tissue was controlled by the inclusion of 10% polyethylene glycol (PEG) QUOTE "31" 31. The tissues were incubated in standard culture medium or osteogenic medium for a minimum of 21 days. Three samples were cultured for 8 weeks and maintained in osteogenic medium plus 50 ng/ml BMP2 with each change of medium having an initial 15 minute transient treatment with 10 nM 1,25-dihydroxyvitamin D3 to activate vitamin D receptors, as previously described by Chen et al QUOTE "32" 32.

Assessment of osteogenic differentiation
In cultured cells, alkaline phosphatase activity was determined either histologically or via a colourimetric assay QUOTE "33" 33.  For histological staining, cells were fixed for 10 mins with 10% formalin, washed with PBS (Life Technologies) then incubated for 1 h at room temperature (RT) with the stain solution:  25 mg naphthol AS-BI phosphate in 0.5 ml dimethylformamide and 50 mg Fast Red TR in 50 ml TrisHCl buffer (pH 9; all Sigma Aldrich).  Cells were washed with PBS and the percentage of cells stained were counted and the staining intensity semi-quantitatively assessed with scores ranging from 1 to 6, representing  light to strong staining intensity.  (All three wells for 1 patient’s cells per condition were viewed in their totality and ascribed an average score for both the number of cells (as a percentage of the total cells) and intensity in their staining.) Where appropriate, alkaline phosphatase activity was also determined via colourimetric assay in a 96-well format.  For this, cells were lysed with 0.1% Triton X in PBS and 50μl of lysate incubated for 1 h at 37°C with 0.7% (v/v) 0.5 M MgCl2 and 1.24% (w/v) para-nitrophenol phosphate in 50 mM sodium carbonate and 50 mM Tris buffer (pH 9.5).  Colour change was read at 405 nm and background absorbance corrected with readings at 650 nm.  
3D explant cultures were assessed for calcification via von Kossa and alizarin red staining. Explants were snap-frozen in liquid nitrogen-cooled hexane and 7 μm thick cryosections were collected onto poly-L-lysine-coated slides and stored at -20°C.  Tissue sections were fixed in 10% formalin for 10 min at RT then either alizarin red solution or 5% solution of silver nitrate (von Kossa) was added with these latter sections needing UV light to develop the stain. Adjacent sections were stained with Mayer’s haematoxylin and eosin (H&E). 

Immunohistochemical staining for BMP inhibitors
Cryosections of explant cultures were also assessed for the presence of BMP inhibitors via immunohistochemistry (IHC).  Slides were brought to RT and ﬁxed in 4% paraformaldehyde for 15 min. All immunostaining steps were carried out at RT and PBS used for each wash unless stated otherwise. Sections were blocked for 1 h with 10% normal horse serum then the following rabbit polyclonal antibodies applied overnight at 4°C: chordin (K-25, sc-130720, 2 µg/ml); gremlin (FL-184, sc-28873, 4 µg/ml); noggin (FL-232, sc-25656, 1 µg/ml) all from Santa Cruz Biotechnology Inc, CA, USA. Negative control sections were incubated with either (i) rabbit normal serum or rabbit IgG (sc-2027, Santa Cruz) at the appropriate concentration or (ii) PBS. Sections were then incubated with secondary biotinylated goat anti-rabbit IgG (Vectastain Elite ABC, Vector Laboratories Ltd, Peterborough, UK) for 30 minutes before blocking for endogenous peroxidise activity with 0.3% hydrogen peroxide in methanol for 30 minutes. Immuno-labelling was visualized using the streptavidin–biotin detection system with diaminobenzidine tetrachloride (Sigma Aldrich) as substrate. Sections were washed with distilled water and dehydrated using serial isopropyl alcohol solutions (70% - 100%) before being cleared in xylene and mounted in Pertex (CellPath, Newtown, UK).

Osteogenic gene expression
In order to determine individual osteogenic genes which could be altered following treatment of monolayer cells for osteogenic differentiation, RNA was extracted using the RNeasy Mini Kit (Qiagen, Manchester, UK).  cDNA was synthesised from extracted RNA using the RT2 First strand kit (Qiagen) and RT-Q PCR performed using an ABI 7500 RT-PCR system (Applied Biosystems) for Runt-related transcription factor 2 (RUNX2), osteocalcin and osteopontin with GAPDH as the reference gene (Qiagen).  Fold changes greater than ±2 were noted and the reference gene expression checked to ensure it was constant throughout.

Statistical analyses 
Statistical analyses were performed using Microscoft Excel and Analyse-It (Analyse-it Software Ltd, Leeds, UK).  Distribution was determined using the Anderson-Darling test for normality and data sets compared using Student’s t-test or one-way analysis of variance (ANOVA) with a Bonferroni post-hoc test. Data is presented as mean +/- standard deviation and significance set at p≤0.05.

Results
Optimal media conditions for osteogenic differentiation of NP cells
Positive staining for alkaline phosphatase activity was seen in all monolayer NP cells treated with osteogenic medium for 21 days, although the extent of staining varied considerably, between patients, both in number (from 10 to 80% of cells) and  intensity (Fig. 1B2-B4, 2B2-B4&  2H1-H3).  The effect of each component of the osteogenic medium (dexamethasone, β-glycerophosphate and L-ascorbic acid-2-phosphate) was also assessed either singularly (Fig. 1C1-C4, 1D1-D4 & 1E1-E4 respectively) or in different combinations (Fig. 1F1-F4, 1G1-G4 & 1H1-H4). Maximal alkaline phosphatase activity was observed in cells treated with complete osteogenic media, with 57 ± 23% of cells having strong positive staining. In particular, dexamethasone and β-glycerophosphate, either individually or in combination increased alkaline phosphatase activity. No relationship between degenerative grade and intensity and percentage cells stained for alkaline phosphatase was observed in this study. As expected, MSCs treated with osteogenic induction medium (Fig. 1B1) stained positively for alkaline phosphatase (75 ± 7%)  though surprisingly, in NP cells maintained in standard culture medium, a small amount of alkaline phosphatase staining was also observed (Fig. 1A2-A4). PCR analysis demonstrated an increase in osteopontin expression, with cells cultured in osteogenic medium to be greatest (45-fold; Fig. 1I) compared to cells maintained in standard culture medium (p<0.01), followed by dexamethasone either in combination with β-glycerophosphate (39-fold, p<0.05), or on its own (17-fold, p<0.05). Osteopontin expression also increased in response to β-glycerophosphate in combination with L-ascorbic acid-2-phosphate (6.5-fold, p<0.0005) and on its own (3.9-fold, p<0.005). At 21 days 2 to 3-fold significant increase in RUNX2 expression was observed when NP cells were cultured with osteogenic or dexamethasone in combination with β-glycerophosphate and also in osteocalcin expression when cultured with β-glycerophosphate alone or in combination with L-ascorbic acid-2-phosphate (all p<0.05). In case any change in RUNX2 expression had been missed by 21 days, the experiment was repeated with an earlier endpoint of 7 days.   A 5-fold increase in RUNX2 expression confirmed our suspicions that this transcription factor is expressed earlier than 21 days in response to osteogenic medium. 
Vit D3 induces osteogenic differentiation
Little or no osteogenic differentiation was seen at 21 days in cells treated with 0.1 nM VitD3 for 21 days (Fig. 2C2-4) with faint alkaline phosphatase staining being present in only approximately 4% of cells. With 1 or 10 nM VitD3, however, some alkaline phosphatase staining was seen in both the NP cells (10%) and MSCs (25-40%; Fig. 2D1-4 & 2E1-4).  Cells treated with complete osteogenic medium were run as a positive control and showed the greatest staining (~45% in NP cells and 80% in MSCs) for alkaline phosphatase (Fig. 2B1-B4).  When added to osteogenic medium, 10nM VitD3 did not augment the alkaline phosphatase activity seen with osteogenic media alone (67 and 65% of cells stained for alkaline phosphatase, respectively; Fig. 2G1-G3 & I1-I3 respectively). Interestingly, PCR analysis detected significantly decreased osteocalcin and osteopontin expression in NP cells maintained in osteogenic medium with 10 nM VitD3 compared to osteogenic without (Figure 2J).

Lack of osteogenic differentiation following application of pTH or BMPs
Neither continuous nor intermittent doses of PTH over the concentration range of 1 to 100 nM increased alkaline phosphatase (assessed both via histological staining or activity assay) in the NP cells or MSCs (data not shown). In addition, there was no observed increase in alkaline phosphatase as assessed by activity assay in NP cells or MSCs treated with BMP2, 7 or 2/7 heterodimer at concentrations between 10 and 100 ng/ml (data not shown), in fact the application of BMPs, in particular BMP2/7, seemed to reduce alkaline phosphatase activity in human NP cells compared to those maintained in standard culture.

3D culture of NP tissue and presence of BMP inhibitors
Calcification was identified in two of the herniated human NP tissues maintained in explant culture (Fig. 3A & B).  Calcification was detected via alizarin red staining in disc tissue isolated from a 29 year old female (L4/5) and maintained in osteogenic media for 21 days and also in disc tissue from a 44 year old male (L5/S1) maintained in osteogenic media with the addition of VitD3 followed by BMP2 for 8 weeks.  All other discs grown as explant cultures showed no induction of mineralisation regardless of culture conditions or time in culture. As in monolayer, degenerate grade did not appear to be associated with calcification of the explant tissues.
	All five of the IVD explants assessed for the presence of the BMP inhibiting molecules chordin, gremlin and noggin within the cells and extracellular matrix were found to be positive for gremlin (Fig. 4D-G), but the number of cells and intensity of staining varied from few and pale to numerous and dark.  Cells were positive for chordin in 3/5 samples whilst noggin was detected in 4 of the samples. Neither chordin nor noggin was clearly detected in any the extracellular matrix of the explants. No clear relationship between the presence of these BMP inhibitors and calcification of the extracellular matrix was observed. 

Discussion
We have shown that human degenerate IVD cells are capable of becoming osteogenic in both monolayer culture and in situ within NP tissue. In monolayer culture, cells from human degenerate NPs, maintained in osteogenic media, were consistently capable of osteogenic differentiation. Some NP cells stained positive for alkaline phosphatase even under standard conditions, indicating a ‘natural’ predilection for, or tendency to becoming osteogenic.  This may reflect the presence of progenitor cells that have previously been identified in disc tissue  QUOTE "14" 14, QUOTE "15" 15, QUOTE "16" 16, QUOTE "34" 34, QUOTE "17" 17.  We have shown that  11-20% of cells within degenerate discs have positive staining for the putative stem cell markers, Notch-1 and cytokeratins 8 and 19, although there is a huge range between individual patients’ discs (eg from 0 to 96% for Notch-1) QUOTE "14" 14. Recent work by Tekari et al QUOTE "35" 35 identified approximately 9% of bovine NP cells as being positive for the angiopoietin-1 receptor (Tie2).  Cells positive for Tie2 have been shown to have progenitor-like multipotency and in human discs their incidence decreases with both age and degeneration QUOTE "34" 34.
Cells express different markers at different stages of osteogenesis. RUNX2 is one of the initial markers prior to alkaline phosphatase production, followed by osteopontin and then osteocalcin QUOTE "36" 36. RUNX2 is a key transcription factor essential for osteoblastic differentiation and is usually expressed early by committed osteoprogenitor cells or immature osteoblasts. The expression of RUNX2 in our experiments was found to be increased at 7 days but by 21 days this upregulation had ceased, typical of its early production in osteogenesis QUOTE "19" 19. The later markers, osteocalcin and osteopontin, are both secreted by mature osteoblasts, but osteopontin is also produced in other tissues. Both these molecules are involved in the regulation of hydroxyapatite formation with osteopontin, in particular, having a role in inhibiting crystal growth QUOTE "37" 37. At 21 days, osteocalcin was significantly upregulated (up to 3-fold) when β-glycerophosphate, either alone or with L-ascorbic acid-2-phosphate, was added to the monolayer cultures. Osteopontin was significantly expressed at high levels during culture with osteogenic media and all culture conditions with dexamethasone except when VitD3 was added. 
Interestingly, factors which are commonly used as osteogenic agents in the clinic (VitD3, PTH and BMPs) had less effect on disc cells and MSCs than osteogenic culture medium traditionally used in in vitro systems. In vivo, the active form of Vitamin D, VitD3, maintains the homeostasis of calcium and phosphate ions and reduces osteoporotic risk QUOTE "38" 38. In osteoblasts, two receptors, one nuclear (vitamin D receptor (VDR)) QUOTE "39" 39 and one in the plasma membrane (protein disulphide isomerase family A member 3 (Pdia3)) QUOTE "40" 40, QUOTE "41" 41, have been identified for VitD3. We found that the lower concentration (0.1 nM) of VitD3 did not stimulate up-regulation of alkaline phosphatase in human degenerate disc cells, but at higher concentrations, such as 1 or 10 nM, alkaline phosphatase activity was increased. A similar response to 10 nM VitD3 has been observed in other studies using MSCs obtained from vertebral bodies whereby this concentration promoted osteogenesis QUOTE "23" 23, QUOTE "24" 24 . At a concentration of 10 nM, VitD3 increased alkaline phosphatase staining in NP cells and MSCs, but did not augment the effect of osteogenic medium, perhaps due to dexamethasone interfering, as has been shown to occur in human osteoblasts QUOTE "42" 42.  In contrast, in response to the addition of VitD3 to osteogenic medium, both osteocalcin and osteopontin expression were significantly decreased in NP cells (compared to osteogenic medium alone) and yet alkaline phosphatase staining remained the same.
In vivo, PTH acts to increase the presence of calcium ions by binding to osteoblasts and increasing RANKL expression but inhibiting osteoprotegerin (OPG) production. RANKL is then free to bind to RANK instead of OPG, thus stimulating osteoclast precursors to fuse and form new osteoclasts which break down bone and release calcium ions from the bone matrix. However, the presence of both intermittent QUOTE "27" 27 and continuous QUOTE "26" 26 application of 1-45 PTH has been shown to induce alkaline phosphatase in rodent MSCs, although Yang et al QUOTE "26" 26 found that intermittent application reduced alkaline phosphatase levels in their rat MSCs to lower than controls and Fujita et al  QUOTE "43" 43 found continuous PTH decreased alkaline phosphatase in mice osteoblasts. Neither intermittent nor continuous application of PTH in this study was found to affect the presence of alkaline phosphatase in human degenerate NP cells. Disc cells may behave differently from MSCs, since Madiraju et al QUOTE "44" 44 applied PTH to degenerate discs cells and found that it reduced alkaline phosphatase activity in human NP cells (but not AF cells). 
BMPs 2 and 7 have long been known to be involved in inducing bone and cartilage formation and in osteoblast (​https:​/​​/​en.wikipedia.org​/​wiki​/​Osteoblast" \o "Osteoblast​) differentiation. They have also been reported to have an anabolic effect on IVD cells and tissues, by increasing proteoglycan and matrix production. Kim et al QUOTE "45" 45 have shown that human NP cells produce alkaline phosphatase and at a higher level by cells from less degenerate discs than more degenerate ones. Injections of BMP7 into canine discs have been shown to stimulate the production of peridiscal bone QUOTE "46" 46.  However, the dose of BMP injected into these discs was more than 1000 fold of that used in the present study where we found no response. It is also known that disc cells are capable of producing inhibitors to osteogenic factors such as BMPs; these include noggin, gremlin and chordin. Chan et al QUOTE "47" 47 have shown that human disc cells express the genes for these antagonists and co-culture of disc cells reduced osteogenesis in MSCs. In addition, expression of GREM1 was higher in NP cells than AF cells. The same group have shown reversal of the discs inhibitory effect on MSCs with the addition of BMP2 (L51P variant) QUOTE "48" 48. Immunohistochemical staining for the BMP inhibitors in our study demonstrated that they were present in some disc samples and to varying degrees.  
There are conflicting reports in the literature about the propensity of NP cells and tissues to mineralise, both in vitro and in vivo. For example, Nosikova et al QUOTE "19" 19 actually used bovine NP cells as a negative control in their in vitro study on mineralisation of AF cells (and our laboratory has found a similar resistance of bovine NP cells to become osteogenic (unpublished results)). There are many pathological syndromes, however, where ectopic calcification of discs occurs naturally in canines, sheep QUOTE "49" 49 and humans. The aetiology of the dystrophic calcification is not known and indeed the calcification process itself is complex such that there are numerous factors that can influence the many pathways involved. Other reasons for the variation of human degenerate IVDs to calcify are that perhaps some discs may have a higher number of progenitor cells (and so be more likely to calcify). This may explain the calcification observed in the NP of the 29 year old in Fig 3A whilst other samples, from older patients, may have lower numbers of progenitor cells. Alternatively some discs may have higher levels of molecules which are known to inhibit mineralisation, such as gremlin, noggin and chordin, which have been investigated here. Other factors which are known to influence the likelihood of calcification, are pH and levels of phosphate, calcium ions, alkaline phosphatase activity and pro-inflammatory cytokines; none of these have been studied here so may be considered as a limitation of this study. A further limitation of the study is due to the lack of adequate cells available from the surgical waste material and being unable to provide enough at an early passage as was preferred for all the replicate tests performed; hence cells were assessed in monolayer at passages varying between P1 and P4. 
Nonetheless, it is an appealing approach to use a biological technique to enable a spinal fusion in those carefully selected patients who are likely to benefit from reduced pain if a particular spinal section can be immobilised. Hence we hope this work will encourage others to determine which factors are likely to be the main orchestrators of mineralisation and in which patients.

Conclusion
This work has shown that cells from degenerate human IVDs have the capability to be driven down an osteogenic pathway, such that they can cause the production of calcium and phosphate salts in their environment. Continuing this process in tissue and in vivo must deal with more complexities, eg if there are conditions such as loading or pH) or particular molecules in the disc (eg inhibitors of calcification) or frequency of progenitor cells, which will vary between people and influence whether the disc matrix will become mineralised. Further developing our understanding of these control points could lead to a relatively simple and minimally invasive approach for fusing the spine in back pain patients in the future, in addition to perhaps explaining why some patients are resistant to BMP2 treatment for spinal fusion. 
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Figure 1 (A-H) Alkaline phosphatase staining of cultured MSCs and human NP cells maintained for 21 days with osteogenic medium (osteo) (B1-4) and its components, dexamethasone (DEX) (C1-4), β-glycerophosphate (B--G) (D1-4), L-ascorbic acid-2-phosphate (AA) (E1-4) and in combination (F1-H4), in comparison to the control of ‘standard’ medium (i-iv). (I) Expression of osteocalcin, osteopontin and RUNX2 genes (relative to GAPDH) for each corresponding culture condition at 21 days. Results show the mean values of NP cell cultures from 3 different patients and the bar represents the standard deviation. Significant differences are denoted by *p<0.05 and **p<0.005. 

Figure 2 (A-E) Alkaline phosphatase staining of cultured human NP cells from 3 patients and one population of MSCs maintained with osteogenic medium (B1-4) and 3 doses of VitD3 (0.1, 1 and 10nM; C1-4, D1-4 and E1-4 respectively) in comparison to standard medium (A1-4) and (F-I) cultured human NP cells from 3 patients exposed to standard and osteogenic medium +/- 10 nM VitD3, all at 21 days. (J) Expression of osteocalcin, osteopontin and RUNX2 genes (relative to GAPDH) for each culture condition in (F-I). Results show the mean values of NP cells cultured from n=3 patients with bars representing the standard deviation. Significant differences between osteogenic media with and without VitD3 are denoted by *p<0.01.

Figure 3 (A) Four representative disc explants cultured in standard and osteogenic culture medium for 21 days and stained with alizarin red. Only the explant from the youngest patient (NP10) showed calcification.. (B) Explant cultures from NP13 cultured in Vit D3 for 15 minutes prior to BMP osteogenic medium for 8 weeks, showing ossification in sections stained with H&E, alizarin red and von Kossa.
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